SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-018117
Filing Date
2019-05-09
Accepted
2019-05-09 17:24:52
Documents
72
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akca-10q_20190331.htm 10-Q 2123194
2 EX-10.1 akca-ex101_176.htm EX-10.1 62401
3 EX-31.1 akca-ex311_9.htm EX-31.1 18992
4 EX-31.2 akca-ex312_8.htm EX-31.2 18983
5 EX-32.1 akca-ex321_10.htm EX-32.1 10939
  Complete submission text file 0001564590-19-018117.txt   8013217

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT akca-20190331.xml EX-101.INS 1723319
7 XBRL TAXONOMY EXTENSION SCHEMA akca-20190331.xsd EX-101.SCH 73165
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akca-20190331_cal.xml EX-101.CAL 61467
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akca-20190331_def.xml EX-101.DEF 238350
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE akca-20190331_lab.xml EX-101.LAB 482340
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akca-20190331_pre.xml EX-101.PRE 372053
Mailing Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210
Business Address 22 BOSTON WHARF RD 9TH FLOOR BOSTON MA 02210 617-207-0202
AKCEA THERAPEUTICS, INC. (Filer) CIK: 0001662524 (see all company filings)

IRS No.: 472608175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38137 | Film No.: 19811895
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences